The hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled study
| Autor: | Lucia Fatima Campos Pedrosa, Maria Sanali Moura de Oliveira Paiva, Karine Cavalcanti Maurício Sena-Evangelista, Tanize do Espirito Santo Faulin, Dulcinéia Saes Parra Abdalla, Paula Cristina Silveira Dias, Diana Quitéria Cabral Ferreira, Silvia Maria Franciscato Cozzolino |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Antioxidant medicine.medical_treatment chemistry.chemical_element lcsh:Medicine Coronary Artery Disease Statistics Nonparametric chemistry.chemical_compound Selenium Internal medicine medicine Humans Rosuvastatin Rosuvastatin Calcium lcsh:Science Hypolipidemic Agents chemistry.chemical_classification Glutathione Peroxidase Multidisciplinary biology medicine.diagnostic_test Cholesterol business.industry Superoxide Dismutase Glutathione peroxidase C-reactive protein lcsh:R Lipids Lipoproteins LDL DOENÇAS CARDIOVASCULARES Zinc Endocrinology C-Reactive Protein Treatment Outcome chemistry Dietary Supplements biology.protein Female lcsh:Q Lipid profile business medicine.drug Research Article |
| Zdroj: | PLoS ONE, Vol 10, Iss 3, p e0119830 (2015) PLoS ONE Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| ISSN: | 1932-6203 |
| Popis: | Objective Statins treatment may modify the levels of zinc and selenium, minerals that can improve vascular function and reduce oxidative damage and inflammation in atherosclerotic patients. This study aimed to evaluate the effects of rosuvastatin, alone or associated with zinc and selenium supplementation, on lipid profile, antioxidant enzymes and mineral status in coronary artery disease patients. Material and Methods A double-blind randomized clinical trial was performed in which patients (n = 76) were treated with 10 mg rosuvastatin over 4 months associated or not with zinc (30 mg/d) and selenium (150 μg/d) supplementation. The following parameters were analyzed before and after the intervention: anthropometric measurements, lipid profile, high sensitivity C-reactive protein (hs-CRP), electronegative low density lipoprotein (LDL(-)) concentrations, activities of glutathione peroxidase (GPx), superoxide dismutase (SOD), zinc and selenium concentrations in blood plasma and erythocytes. Significance was determined using an α of 5% (two-tailed). Results We found that rosuvastatin therapy was efficient in reducing total cholesterol, LDL-cholesterol, non-HDL cholesterol, triglycerides, and hs-CRP independently of mineral supplementation. Neither treatment was associated with significant changes in LDL(-). Similarly, the antioxidant enzymes GPx and SOD activity were unchanged by treatments. Neither treatment was associated with significant differences in concentrations of zinc or selenium in blood plasma and erythocytes of studied groups. Conclusion Rosuvastatin treatment did not affect zinc and selenium levels in coronary artery disease patients. The zinc and selenium supplementation at doses used in this study did not change lipid profile or SOD and GPx activity in patients receiving rosuvastatin. Further studies should be focused on testing alternative doses and supplements in different populations to contribute for a consensus on the ideal choice of antioxidants to be used as possible complementary therapies in atherosclerotic patients. Trial Registration ClinicalTrials.gov NCT01547377 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|